Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
Although small cell lung cancer (SCLC) is highly responsive to chemotherapies (e.g., cisplatin-etoposide doublet), virtually almost all responsive SCLC patients experience disease recurrence characterized by drug resistance. The mechanisms underlying cisplatin resistance remain elusive. Here we repo...
Main Authors: | Fei Yan, Jiuxia Pang, Yong Peng, Julian R Molina, Ping Yang, Shujun Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5017656?pdf=render |
Similar Items
-
The intrinsic PD-L1 promotes cellular invasiveness via their PD-1 receptor in lung adenocarcinoma cells
by: Shuen-RuYang, et al.
Published: (2017) -
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
by: Ranjan Pathak, et al.
Published: (2020-12-01) -
PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
by: Minghui Liu, et al.
Published: (2021-03-01) -
Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer
by: Zhansheng JIANG, et al.
Published: (2017-02-01) -
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
by: Jing W, et al.
Published: (2016-01-01)